natgillin/translations-raw huggingface dataset:
Patients co-infected with hepatitis B and/or hepatitis C virus Among 1,151 patients receiving atazanavir 400 mg once daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg once daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C. Coinfected patients were more likely to have baseline hepatic transaminase elevations than those without chronic viral hepatitis. 
Bolesnici istovremeno zaraženi virusom hepatitisa B ili C Od 1151 bolesnika koji su primali atazanavir 400 mg jedanput na dan, 177 bolesnika istovremeno je imalo kroničnu infekciju virusom hepatitisa B ili C, dok je od 655 bolesnika koji su primali atazanavir 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan, 97 bolesnika istovremeno imalo kroničnu infekciju virusom B ili C.
Sildenafil, tadalafil and vardenafil are metabolised by CYP3A4. 
Sildenafil, tadalafil i vardenafil metabolizira enzim CYP3A4.
Co-administration of quetiapine with atazanavir is contraindicated as atazanavir may increase quetiapine-related toxicity. 
Istodobna primjena kvetiapina i atazanvira je kontraindicirana jer atazanavir može povećati toksičnost povezanu s primjenom kvetiapina.
Norethindrone AUC ↑110% 
Norbuprenorfin AUC ↑105%
De novo substitutions in treatment naive patients failing therapy with atazanavir + ritonavir (Study 138, 96 weeks) 
De novo supstitucije u bolesnika koji prethodno nisu bili liječeni i u kojih je podbacila terapija atazanavirom s ritonavirom (Ispitivanje 138, 96 tjedana)
Atazanavir Krka Dose once daily (mg) 
Atazanavir Krka doza jedanput na dan (mg)
The recommended adult dose of Atazanavir Krka capsules is 300 mg once daily with 100 mg ritonavir once daily and with food, in combination with other anti-HIV medicines. 
Preporučena doza Atazanavir Krka kapsula za odrasle je 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan i s hranom, u kombinaciji s drugim anti-HIV lijekovima.
Also see PULMONARY ARTERIAL HYPERTENSION in this table for futher information regarding co- administration of atazanavir with sildenafil. 
ARTERIJSKA HIPERTENZIJA u ovoj tablici za dodatne informacije o istovremenoj primjeni atazanvira i sildenafila.
Withdrawal of ritonavir only under restrictive conditions The recommended standard treatment is Atazanavir Krka boosted with ritonavir, ensuring optimal pharmacokinetic parameters and level of virologic suppression. 
Preporučeni standardni režim liječenja je Atazanavir Krka pojačan ritonavirom, čime se osiguravaju optimalni farmakokinetički parametri i optimalna razina virološke supresije.
300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil. 
300 mg tenofovirdizoproksilfumarata što odgovara 245 mg tenofovirdizoproksila.
Co-administration with atazanavir has the potential to increase or decrease warfarin concentrations. 
Istovremena primjena s atazanvirom može povisiti ili sniziti koncentracije varfarina.
Stop taking Atazanavir Krka and talk to your doctor immediately if you develop a severe rash or a rash with flu-like illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling in the face, inflammation of the eye which causes redness (conjunctivitis), painful, warm, or red lumps (nodules). 
Krka i obratite se liječniku ako se u Vas razviju teški osip ili osip sa simptomima bolesti nalik gripi, mjehurići, vrućica, ranice u ustima, bol u mišićima ili zglobovima, oticanje lica, upala oka koja uzrokuje crvenilo (konjunktivitis),bolni, topli ili crveni čvorići (noduli).
Co-administration with atazanavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5inhibitor-associated adverse events. 
Istovremena primjena s atazanavirom može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s inhibitorom PDE5.
common: fatigue; uncommon: chest pain, malaise, pyrexia, asthenia; rare: gait disturbance aThese adverse reactions were identified through post-marketing surveillance, however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to atazanavir in randomised controlled and other available clinical trials (n = 2321). 
rijetko: poremećaj hoda a Ove su nuspojave utvrđene u razdoblju nakon stavljanja lijeka u promet, premda, učestalost je procijenjena statističkim izračunom na temelju ukupnog broja bolesnika izloženih atazanaviru u randomiziranim kontroliranim i drugim dostupnim kliničkim ispitivanjima (n = 2321).
Atazanavir Krka given without ritonavir should not be considered in patients treated with a backbone regimen containing tenofovir disoproxil and with other concomitant medications that reduce atazanavir bioavailability (see section 4.5 In case of withdrawal of ritonavir from the recommended atazanavir boosted regimen) or in case of perceived challenging compliance. 
Primjena lijeka Atazanavir Krka bez ritonavira ne smije se razmatrati u bolesnika liječenih osnovnim režimom koji sadrži tenofovirdizoproksil i drugim istovremeno primjenjivanim lijekovima koji smanjuju bioraspoloživost atazanavira (vidjeti odlomak "Ako se ritonavir izostavi iz preporučenog režima liječenja atazanavirom pojačanim ritonavirom" u dijelu 4.5), kao ni u bolesnika za koje se smatra da bi mogli imati poteškoća s pridržavanjem liječenja.
The co-administration of abacavir and atazanavir is not expected to significantly alter the exposure of abacavir. 
Ne očekuje se da će istovremena primjena abakavira i atazanvira značajno promijeniti izloženost abakaviru.
The geometric mean (CV%) for atazanavir cmin and AUC were 120 (109) ng/ml and 14874 (91) ng•h/ml, respectively. 
Geometrijska srednja vrijednost (CV%) Cmin atazanavira iznosila je 120 (109) ng/ml, a AUC atazanavira 14874 (91) ng•h/ml.
The capsule cap is imprinted with black mark A150. 
Na kapici kapsule je utisnuta crna oznaka A150.
If you stop taking Atazanavir Krka Do not stop taking Atazanavir Krka before talking to your doctor. 
Nemojte prestati uzimati Atazanavir Krka prije nego što o tome razgovarate s Vašim liječnikom.
common: headache; uncommon: peripheral neuropathy, syncope, amnesia, dizziness, somnolence, dysgeusia 
manje često: periferna neuropatija, sinkopa, amnezija, omaglica, somnolencija, disgeuzija
The geometric mean (CV%) for atazanavir cmin and AUC was 654 (76%) ng/ml and 44185 (51%) ng•h/ml, respectively. 
Geometrijska sredina (CV%) Cmin atazanavira iznosila je 654 (76%) ng/ml, a AUC atazanavira 44185 (51%) ng•h/ml.
In an open-label, randomised, comparative study following a 26- to 30-week induction phase with atazanavir 300 mg + ritonavir 100 mg once daily and two NRTIs, unboosted atazanavir 400 mg once daily and two NRTIs administered during a 48-week maintenance phase (n=87) had similar antiviral efficacy compared with atazanavir + ritonavir and two NRTIs (n=85) in HIV infected subjects with fully suppressed HIV replication, as assessed by the proportion of subjects with HIV RNA < 50 copies/ml: 78% of subjects on unboosted atazanavir and two NRTIs compared with 75% on atazanavir + ritonavir and two NRTIs. 
U otvorenom, randomiziranom, usporednom ispitivanju provedenom nakon 26 do 30 tjednog uvodnog liječenja atazanavirom u dozi od 300 mg + ritonavirom u dozi od 100 mg jedanput na dan i dvama NRTI-ma u ispitanika s HIV infekcijom i potpuno suprimiranom replikacijom HIV-a, kombinacija nepojačanog atazanavira u dozi od 400 mg jedanput na dan i dvaju NRTI-ja tijekom 48-tjedne faze održavanja (n=87) postigla je sličnu antivirusnu djelotvornost kao i atazanavir + ritonavir i dva NRTIja (n=85), što je utvrđeno na temelju udjela ispitanika s HIV RNK < 50 kopija/ml: 78% ispitanika liječenih nepojačanim atazanavirom i dvama NRTI-ma u usporedbi sa 75% ispitanika liječenih atazanavirom s ritonavirom i dvama NRTI-ma.
tenofovir disoproxil fumarate in treatment- experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1). 
Djelotvornost atazanvira s ritonavirom u kombinaciji s tenofovirdizoproksilfumaratom u prethodno liječenih bolesnika dokazana je u kliničkom ispitivanju 045, a u bolesnika koji prethodno nisu bili liječeni u kliničkom ispitivanju 138 (vidjeti dijelove 4.8 i 5.1).
Particular caution should be used when prescribing Atazanavir Krka in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3). 
Atazanavir Krka propisuje zajedno s drugim lijekovima koji mogu produljiti QT interval i/ili u bolesnika s već prisutnim čimbenicima rizika (bradikardija, kongenitalno produljeni QT interval, poremećaji elektrolita) (vidjeti dijelove 4.8 i 5.3).
uncommon: torsades de pointes a rare: QTc prolongationa, oedema, palpitation 
manje često: torsades de pointes a rijetko: produljenje QTc intervala a, edem, palpitacije
Body: titanium dioxide (E171) and gelatine 
Tijelo: titanijev dioksid (E171) i želatina
Three of 20 infants (15%) born to women treated with atazanavir /ritonavir 300/100 mg and four of 20 infants (20%) born to women treated with atazanavir /ritonavir 400/100 mg experienced grade 3-4 bilirubin. 
Troje od 20 dojenčadi (15%) žena liječenih s atazanavirom/ritonavirom 300/100 mg i četvero od 20 dojenčadi (20%) žena liječenih s atazanavirom/ritonavirom 400/100 mg imalo je bilirubin 3.-4. stupnja.
Carbamazepine should be used with caution in combination with atazanavir. 
Karbamazepin se mora primjenjivati uz oprez u kombinaciji s atazanvirom.
Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). 
Mehanizam djelovanja Atazanavir je azapeptidni inhibitor proteaze virusa HIV-1.
14-OH clarithromycin cmax ↓72% 14-OH clarithromycin cmin ↓62% 
14-OH klaritromicin Cmax ↓72% (↓76% 14-OH klaritromicin Cmin ↓62% (↓66%
Atazanavir and fluconazole concentrations were not significantly modified when atazanavir /ritonavir was coadministered with fluconazole. 
Koncentracije atazanavira i flukonazola nisu bile značajno promijenjene kad se atazanvir s ritonavirom primjenjivao istovremeno s flukonazolom.
België/Belgique/Belgien KRKA Belgium, SA. 
België/Belgique/Belgien
Co-administration of atazanavir with triazolam or orally administered midazolam is contraindicated (see section 4.3), whereas caution should be used with co- administration of atazanavir and parenteral midazolam. 
Istovremena primjena atazanavira s triazolamom ili peroralno primijenjenim midazolamom je kontraindicirana (vidjeti dio 4.3), dok je oprez potreban kod istovremene primjene atazanavira i parenteralnog midazolama.
HDPE tablet container with child-resistant tamper evident PP with desiccant closure: 30 hard capsules and 90 (3 x 30) hard capsules, in a box. 
HDPE spremnik za tablete sa polipropilenskim zaštitnim zatvaračem sigurnim za djecu s evidencijom otvaranja i sredstvom za sušenje: 30 tvrdih kapsula i 90 (3 x 30) tvrdih kapsula u kutiji.
Buprenorphine AUC ↑67% Buprenorphine cmax ↑37% Buprenorphine cmin ↑69% 
Buprenorfin Cmax ↑37% Buprenorfin Cmin ↑69%
Six of 20 (30%) women on atazanavir /ritonavir 300/100 mg and 13 of 21 (62%) women on atazanavir /ritonavir 400/100 mg experienced grades 3 to 4 hyperbilirubinaemia. 
Šest od 20 (30%) žena koje su primale atazanavir/ritonavir 300/100 mg i 13 od 21 (62%) žene koje su primale atazanavir/ritonavir 400/100 mg razvilo je hiperbilirubinemiju 3. do 4. stupnja.
When Atazanavir Krka and ritonavir are co-administered, the metabolic drug interaction profile for ritonavir may predominate because ritonavir is a more potent CYP3A4 inhibitor than atazanavir. 
Kod istovremene primjene lijeka Atazanavir Krka i ritonavira može prevladavati metabolički profil interakcija za ritonavir, zato što je ritonavir jači inhibitor enzima CYP3A4 od atazanavira.
Concomitant use of Atazanavir Krka /ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5). 
Ne preporučuje se istovremena primjena lijeka Atazanavir Krka/ritonavir i flutikazona ili drugih kortikosteroida koje metabolizira enzim CYP3A4, osim ako je moguća korist liječenja veća od rizika od učinaka sistemskih kortikosteroida, uključujući Cushingov sindrom i supresiju nadbubrežne žlijezde (vidjeti dio 4.5).
Quinidine has a narrow therapeutic window and is contraindicated due to potential inhibition of CYP3A by atazanavir. 
Kinidin ima usku terapijsku širinu i kontraindiciran je zbog moguće inhibicije enzima CYP3A atazanvirom.
Absorption: in HIV-infected patients (n=33, combined studies), multiple dosing of atazanavir 300 mg once daily with ritonavir 100 mg once daily with food produced a geometric mean (CV%) for atazanavir, cmax of 4466 (42%) ng/ml, with time to cmax of approximately 2.5 hours. 
Apsorpcija: U bolesnika zaraženih HIV-om (n=33, kombinirana ispitivanja), višestruka primjena atazanavira 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan s hranom dovela je do geometrijske sredine (CV%) Cmax atazanavira od 4466 (42%) ng/ml, uz vrijeme do postizanja Cmax od približno 2,5 sati.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and coadministration with atazanavir may result in increased concentrations. 
Metabolizam simvastatina i lovastatina jako ovisi o enzimu CYP3A4 i istovremena primjena s atazanvirom može rezultirati povišenim koncentracijama.
The M184I/V substitution emerged in 5/26 atazanavir /ritonavir and 7/26 lopinavir/ritonavir virologic failure patients, respectively. 
Supstitucija M184I/V bila je prisutna u 5 od 26 bolesnika u kojih liječenje atazanavirom s ritonavirom nije bilo virološki uspješno i 7 od 26 bolesnika u kojih liječenje lopinavirom/ritonavirom nije bilo virološki uspješno.
Atazanavir Krka 150 mg and 200 mg hard capsules are available in containers containing 60 hard capsules; in a box. 
Atazanavir Krka 150 mg i 200 mg tvrde kapsule su dostupne u spremnicima koji sadrže 60 tvrdih kapsula; u kutiji.
Overall in this study, 182 paediatric patients (81 antiretroviral-naive and 101 antiretroviral-experienced) received once daily atazanavir (capsule or powder formulation), with or without ritonavir, in combination with two NRTIs. 
(81 koji prethodno nisu bili liječeni i 101 prethodno liječeni antiretrovirusnim lijekovima) primala atazanavir (kapsule ili u prašku) jedanput na dan, s ritonavirom ili bez njega, u kombinaciji s dva NRTI-ja.
If you forget to take Atazanavir Krka 
Ako ste zaboravili uzeti Atazanavir Krka
Co-administration of atazanavir with ritonavir and proton pump inhibitors is not recommended. 
Ne preporučuje se istovremena primjena atazanvira s ritonavirom i inhibitorima protonske pumpe.
(n=90 
(n=90e)
RNA level was 4.4 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml). 
HIV-1 RNK u plazmi bila je 4,4 log10 kopija/ml (raspon: 2,6 do 5,88 log10 kopija/ml).
- It is not recommended to use Atazanavir Krka with ritonavir for pregnant patients who are receiving both tenofovir disoproxil and an H2-receptor antagonist. 
Ne preporučuje se primjenjivati Atazanavir Krka s ritonavirom u trudnica koje primaju i tenofovirdizoproksil i antagonist
Therefore, postpartum patients should be closely monitored for adverse reactions. 
bolesnice u postpartalnom razdoblju treba pažljivo pratiti zbog nuspojava.
- Atazanavir Krka may affect how well your kidneys work. 
- Atazanavir Krka može utjecati na to kako dobro rade vaši bubrezi.
Other medicines and Atazanavir Krka 
Drugi lijekovi i Atazanavir Krka
Co-administration of Atazanavir Krka with these medicinal products is expected to substantially increase their concentrations and may result in PDE5associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5). 
Pri istovremenoj primjeni lijeka Atazanavir Krka i ovih lijekova očekuje se znatno povećanje njihove koncentracije, što može rezultirati nuspojavama povezanima s PDE5, kao što su hipotenzija, poremećaji vida i prijapizam (vidjeti dio 4.5).
Concomitant use of salmeterol and Atazanavir Krka may result in increased cardiovascular adverse events associated with salmeterol. 
Istovremena primjena salmeterola i lijeka Atazanavir Krka može rezultirati pojačanim kardiovaskularnim nuspojavama salmeterola.
Hepatic impairment: Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 4.3). 
Oštećenje funkcije jetre: Atazanavir se prvenstveno metabolizira u jetri, pa su u bolesnika s oštećenjem funkcije jetre bile opažene povišene koncentracije atazanavira u plazmi (vidjeti dijelove 4.2 i 4.3).
Co-administration of simvastatin or lovastatin with atazanavir is contraindicated due to an increased risk of myopathy including rhabdomyolysis (see section 4.3). 
Kontraindicirana je istovremena primjena simvastatina ili lovastatina s atazanvirom zbog povišenog rizika od miopatije uključujući rabdomiolizu (vidjeti dio 4.3).
Week 48: -3% [-7.6%, 1.5%] Week 96: 2.2% [-2.3%, 6.7%] HIV RNA <50 copies/ml, % by Baseline Characteristic d 
48. tjedan: -3% [-7,6%, 1,5%] 96. tjedan: 2,2% [-2,3%, 6,7%]
Phenobarbital and phenytoin should be used with caution in combination with atazanavir /ritonavir. 
Fenobarbital i fenotoin se moraju primjenjivati uz oprez u kombinaciji s atazanvirom i ritonavirom.
Co-administration of atazanavir with voxilaprevir-containing products is expected to increase the concentration of voxilaprevir. 
Očekuje se da istodobna primjena atazanavira s lijekovima koji sadrže voksilaprevir povećava koncentraciju voksilaprevira.
When treating HIV infection, it is not always easy to identify what side effects are caused by Atazanavir 
Kod liječenja HIV-infekcije nije uvijek lako utvrditi koje su nuspojave izazvane lijekom Atazanavir Krka, koje drugim lijekovima koje uzimate, a koje samom HIV-infekcijom.
↔ Atazanavir ↔ Ritonavir 
Očekivano: ↔ Atazanavir ↔ Ritonavir
Therefore, Atazanavir Krka is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). 
Stoga je Atazanavir Krka kontraindiciran s lijekovima koji su supstrati enzima CYP3A4 i imaju usku terapijsku širinu, kao što su: kvetiapin, lurasidon, alfuzozin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralno primijenjen midazolam i alkaloidi ergota, osobito ergotamin i dihidroergotamin (vidjeti dio 4.3).
No drug interaction study has been performed for the coadministration of atazanavir with benzodiazepines. 
Nisu provedena ispitivanja interakcija lijekova kod istovremene primjene atazanavira i benzodiazepina.
Consistent results were obtained with the last observation carried forward method of analysis (time-averaged difference of 0.11, 97.5% confidence interval [-0.15, 0.36]). 
97,5% interval pouzdanosti [-0,15, 0,36]) dobiveni su dosljedni rezultati.
De novo substitutions in treatment experienced patients failing therapy with atazanavir + ritonavir (Study 045, 48 weeks) 
Tablica 4. De novo supstitucije u prethodno liječenih bolesnika u kojih terapija atazanavirom s ritonavirom nije bila uspješna (Ispitivanje 045, 48 tjedana)
Atazanavir Krka may affect how well your kidneys work. 
Atazanavir Krka može utjecati na to kako dobro rade vaši bubrezi.
The combination of rifampicin and atazanavir is contraindicated (see section 4.3). 
Kombinacija rifampicina i atazanvira je kontraindicirana (vidjeti dio 4.3).
Co-administration of Atazanavir Krka and medicinal products that induce CYP3A4 is not recommended (see sections 4.3 and 4.5). 
Atazanavir Krka i lijekova koji induciraju CYP3A4 (vidjeti dijelove 4.3 i 4.5).
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5). 
Istovremena primjena s lijekovima koji su supstrati izoenzima CYP3A4 citokroma P450 i imaju usku terapijsku širinu (npr. kvetiapin, lurasidon, alfuzozin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralno primijenjen midazolam (za mjere opreza kod parenteralno primijenjenog midazolama vidjeti dio 4.5) i alkaloidi ergota, osobito ergotamin, dihidroergotamin, ergonovin, metilergonovin) (vidjeti dio 4.5).
HIV RNA Mean Change from Baseline, log10 copies/ml 
HIV RNK prosječna promjena od početne vrijednosti, log10 kopija/ml
(400 mg/ 100 mg twice daily (n=123) 
(400 mg/ 100 mg dvaput na dan) n=123
400 mg with ritonavir 100 mg with TDM may be considered (see sections 4.6 and 5.2). 
100 mg uz praćenje koncentracije lijeka (vidjeti dijelove 4.6 i 5.2).
, vesiculobullous rash, eczema, 
, vezikulobulozni osip, ekcem,
ritonavir AUC ↓ 36% ritonavir cmax ↓ 27% ritonavir cmin ↓ 45% 
ritonavir Cmax ↓ 27% ritonavir Cmin ↓ 45%
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA <400 copies/ml (<50 copies/ml) for atazanavir + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%). 
udio bolesnika s HIV RNK <400 kopija/ml (<50 kopija/ml) u skupini koja je primala atazanavir s ritonavirom iznosio je 84% (72%), a u skupini koja je primala lopinavir s ritonavirom 82% (72%).
Alternative antiretroviral therapy to Atazanavir Krka may be considered if jaundice or scleral icterus is unacceptable to a patient. 
Može se razmotriti primjena drugih antiretrovirusnih lijekova ako su žutilo kože ili sklera bolesniku neprihvatljivi.
This side effect is usually not dangerous in adults and infants older than 3 months of age; but it might be a symptom of a serious problem. 
Ta nuspojava obično nije opasna u odraslih i dojenčadi starijoj od
Data on withdrawal of ritonavir from atazanavir boosted regimen (see also section 4.4) Study 136 (INDUMA) 
Podaci o ukidanju ritonavira iz režima pojačanog atazanavirom (vidjeti dio 4.4)
Concentrations of these immunosuppressants may be increased when co-administered with atazanavir due to CYP3A4 inhibition. 
Koncentracije ovih imunosupresiva mogu biti povišene kad se primjenjuju istovremeno s atazanvirom zbog inhibicije CYP3A4.
Table 1: Dose for paediatric patients (6 years to less than 18 years of age and weighing at least 15 kg) for Atazanavir Krka capsules with ritonavir Body Weight (kg) 
Tablica 1: Doza Atazanavir Krka kapsula s ritonavirom za pedijatrijske bolesnike (u dobi od 6 do manje od 18 godina i tjelesne težine od najmanje 15 kg) Tjelesna težina (kg)
Cmax ng/mL Geometric mean (CV%) AUC ng•h/mL Geometric mean (CV%) 
Geometrijska sredina (CV%) AUC ng•h/mL
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2- blockers. 
Mehanizam interakcije je smanjenje topljivosti atazanavira s povećanjem želučanog pH zbog H2 blokatora.
Co-administration of a single 300 mg dose of atazanavir and 100 mg dose of ritonavir with a light meal resulted in a 33% increase in the AUC and a 40% increase in both the cmax and the 24 hour concentration of atazanavir relative to the fasting state. 
100 mg uz lagani obrok rezultirala je povećanjem AUC-a za 33% i povećanjem Cmax i 24-satne koncentracije atazanavira za 40% u odnosu na primjenu natašte.
For randomised patients, the mean time of prior antiretroviral exposure was 138 
Prosječno trajanje prethodne izloženosti randomiziranih bolesnika antiretrovirusnim lijekovima iznosilo je 138 tjedana za inhibitore proteaze,
Co-administration with atazanavir may result in increased concentrations of salmeterol and an increase in salmeterolassociated adverse events. 
Istovremena primjena s atazanvirom može rezultirati povišenim koncentracijama salmeterola i pojačanim nuspojavama povezanima sa salmeterolom.